<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754923</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-08017</org_study_id>
    <secondary_id>NCI-2011-03192</secondary_id>
    <nct_id>NCT00754923</nct_id>
  </id_info>
  <brief_title>Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Study of Single Agent Sorafenib in Non-small Cell Lung Cancer Patients Who Never Smoked or Were Former Light Smokers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth and by blocking blood flow to the tumor.

      PURPOSE: This phase II trial is studying how well sorafenib works in treating non-smokers or
      former light smokers with relapsed or refractory stage IIIB or stage IV non-small cell lung
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the efficacy of sorafenib tosylate, in terms of 6-month progression-free
           survival rate, in non-smokers or former light smokers with relapsed or refractory stage
           IIIB or IV non-small cell lung cancer.

      Secondary

        -  To determine the 1-year survival rate in patients treated with this drug.

        -  To assess the frequency and severity of adverse events associated with this drug in
           these patients.

        -  To investigate the mutational status of EGFR (epidermal growth factor receptor), ALK
           (anaplastic lymphoma kinase), ROS1, and K-Ras(Kirsten rat sarcoma viral oncogene
           homolog)in archived tumor samples from these patients.

      OUTLINE: Patients receive oral sorafenib tosylate twice daily on days 1-28. Courses repeat
      every 28 days in the absence of disease progression or unacceptable toxicity.

      Archived tumor tissue samples are analyzed for mutations of EGFR, ALK, ROS1, and K-Ras by PCR
      (polymerase chain reaction) and DNA (deoxyribonucleic acid) sequencing.

      After completion of study treatment, patients are followed every 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">October 2008</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions&quot;, or similar definition as accurate and appropriate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2008-present</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>2008-present</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mutational Status for EGFR or Kras</measure>
    <time_frame>2008-present</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment: Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib will be administered at a dose of 400 mg taken twice daily, continuously on a 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib</intervention_name>
    <description>administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient.</description>
    <arm_group_label>Treatment: Sorafenib</arm_group_label>
    <other_name>Nexavar</other_name>
    <other_name>sorafenib tosylate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed non-small cell lung cancer

               -  Stage IIIB or IV disease

               -  Recurrent disease after prior surgery, chemotherapy, or radiotherapy

               -  No squamous cell histology or mixed tumor with &gt; 50% squamous cells

          -  Non-smoker (smoked ≤ 100 cigarettes in lifetime) OR former light smoker (smoked &gt; 100
             cigarettes but ≤ 10 pack years AND quit smoking ≥ 1 year ago)

          -  No known brain metastasis

               -  Patients with neurological symptoms must undergo a CT scan or MRI of the brain to
                  exclude brain metastasis

        PATIENT CHARACTERISTICS:

          -  ECOG(Eastern Cooperative Oncology Group)performance status 0-2

          -  ANC (Absolute Neutrophil Count)≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  ALT (Alanine Aminotransferase Test) and AST (Aspartate Aminotransferase Test) ≤ 2.5
             times upper limit of normal (ULN)

          -  Alkaline phosphatase ≤ 2.5 times ULN

          -  Bilirubin ≤ 1.5 mg/dL

          -  Creatinine clearance ≥ 50 mL/min

          -  INR (International Normalized Ratio) &lt; 1.5 OR PT/PTT (Prothrombin time/partial
             thromboplastin time)normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception prior to, during, and for ≥
             3 months after completion of study treatment

          -  No cardiac disease, including any of the following:

               -  New York Heart Association class III-IV congestive heart failure

               -  Unstable angina (anginal symptoms at rest)

               -  New-onset angina within the past 3 months

               -  Myocardial infarction within the past 6 months

          -  No cardiac ventricular arrhythmias requiring anti-arrhythmic therapy

          -  No uncontrolled hypertension (i.e., systolic blood pressure [BP] &gt; 150 mm Hg or
             diastolic BP &gt; 90 mm Hg) despite optimal medical management

          -  No thrombolic or embolic events (e.g., cerebrovascular accident, including transient
             ischemic attacks) within the past 6 months

          -  No pulmonary hemorrhage or bleeding event ≥ CTCAE (Common Terminology Criteria for
             Adverse Events)grade 2 within the past 4 weeks

          -  No other hemorrhage or bleeding event ≥ CTCAE grade 3 within the past 4 weeks

          -  No active clinically serious infection &gt; CTCAE grade 2

          -  No serious non-healing wound, ulcer, or bone fracture

          -  No evidence or history of bleeding diathesis or coagulopathy

          -  No known HIV infection or chronic hepatitis B or C

          -  No other malignancy except for any of the following:

               -  Adequately treated basal cell or squamous cell skin cancer

               -  In situ cervical cancer

               -  Other cancer from which the patient has been disease-free for ≥ 5 years with a
                  low probability of recurrence

          -  No condition that impairs the patient's ability to swallow whole pills

          -  No malabsorption problems

          -  No known or suspected allergy to sorafenib tosylate or any agent given in the course
             of this study

          -  No significant traumatic injury within the past 4 weeks

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No more than one prior systemic chemotherapy treatment for metastatic disease

               -  Prior treatment with EGFR inhibitors is not considered chemotherapy

          -  More than 4 weeks since prior major surgery or open biopsy

          -  No prior sorafenib tosylate

          -  No concurrent St. John's wort or rifampin

          -  Concurrent anticoagulation with warfarin or heparin allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel A. Villalona, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>Jamesline</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2008</study_first_submitted>
  <study_first_submitted_qc>September 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <results_first_submitted>April 15, 2014</results_first_submitted>
  <results_first_submitted_qc>May 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 4, 2014</results_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment: Sorafenib</title>
          <description>Sorafenib will be administered at a dose of 400 mg taken twice daily, continuously on a 28 day cycle.
sorafenib: administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment: Sorafenib</title>
          <description>Sorafenib will be administered at a dose of 400 mg taken twice daily, continuously on a 28 day cycle.
sorafenib: administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" lower_limit="49" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival at 6 Months</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions&quot;, or similar definition as accurate and appropriate</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment: Sorafenib</title>
            <description>Sorafenib will be administered at a dose of 400 mg taken twice daily, continuously on a 28 day cycle.
sorafenib: administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival at 6 Months</title>
          <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions&quot;, or similar definition as accurate and appropriate</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>2008-present</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity</title>
        <time_frame>2008-present</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mutational Status for EGFR or Kras</title>
        <time_frame>2008-present</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment: Sorafenib</title>
            <description>Sorafenib will be administered at a dose of 400 mg taken twice daily, continuously on a 28 day cycle.
sorafenib: administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient.</description>
          </group>
        </group_list>
        <measure>
          <title>Mutational Status for EGFR or Kras</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment: Sorafenib</title>
          <description>Sorafenib will be administered at a dose of 400 mg taken twice daily, continuously on a 28 day cycle.
sorafenib: administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash/hand-foot syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was discontinued, after withdrawal from the sponsor due to slow accrual. The discovery of EGFR mutations changed the scope of the trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Miguel Villalona</name_or_title>
      <organization>OSU</organization>
      <phone>614-366-5068</phone>
      <email>miguel.villalona@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

